300685SZSE
🚨 Material Event

Announcement on the Planning of the Change of Company Control and Continued Suspension of Trading

Amoy Diagnostics Co., Ltd.··2 pages

✨ AI Summary

Xiamen Ad Biomedicine plans to change its controlling shareholder and actual controller, leading to a suspension of trading to protect investor interests. The company announced an initial suspension from June 1, 2026, for up to two trading days. Due to ongoing progress and uncertainties, trading will be further suspended from June 3, 2026, for up to three additional trading days.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300685 Securities Abbreviation: Ad Biomedicine Announcement No.: 2026-035 Xiamen Ad Biomedicine Inc. Announcement on the Planning of the Change of Company Control and Continued Suspension of Trading The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.

Overview of Trading Suspension

Xiamen Ad Biomedicine Inc. (hereinafter referred to as the "Company")'s controlling shareholder, Qianzhan Investment (Hong Kong) Co., Ltd., is planning a change of company control. This matter may lead to a change in the Company's controlling shareholder and actual controller. To protect investor interests and avoid a significant impact on the Company's stock price, upon application to the Shenzhen Stock Exchange, the Company's shares (Securities Abbreviation: Ad Biomedici

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.